ALK and lung adenocarcinoma: Therefore, among the never-smoker lung adenocarcinoma cases without any known driver alterations in oncogenes such as EGFR, KRAS, ALK, etc., the estimated fraction of BCAR4 fusion could be approximately 2.2% (1/44).